Company profile · Vilnius, Lithuania

Northway Biotech

Biopharmaceuticals · Commercial CDMO

BIO CITY anchor with Grade A-D cleanrooms, biologics development-to-manufacturing transfer capability, and bioreactor infrastructure extending to 2,000 L.

Lead
Vladas Algirdas Bumelis (verified ↗)
Address
Mokslininku str. 4, LT-08412 Vilnius, Lithuania (source ↗)
Compliance
cGMP Manufacturing · GMP Certified · ISO 13485
Last reviewed
14 Mar 2026 (3mo ago)
Scale
Commercial CDMO
Capabilities
Mammalian Cell Culture · Microbial Fermentation · Aseptic Filling
Founded
2004
Headcount
51-200
LinkedIn
Company page (open ↗)
Site and address
Clinical profileSTATUS: VERIFIED MARCH 2026

Vladas Algirdas Bumelis

CEO and Chairman of the Board

Check official leadership source
Full addressMokslininku str. 4, LT-08412 Vilnius, Lithuania
Site coordinates54.754063, 25.262225
Review cycleMay 2026
Physical site source

Official Northway Biotech Europe facilities page listing Mokslininku str. 4, Vilnius.

Open source
Operating profile

Commercial CDMO

Vilnius, Lithuania. Biopharmaceuticals. Review completed on 14 Mar 2026.

2026 technical specializationBiopharmaceuticals
Core capabilities
Mammalian Cell CultureMicrobial FermentationAseptic FillingProcess Development
Governance

European Medicines Agency (EMA)

cGMP Manufacturing, GMP Certified, ISO 13485

Editorial note

Biopharmaceuticals

BIO CITY anchor with Grade A-D cleanrooms, biologics development-to-manufacturing transfer capability, and bioreactor infrastructure extending to 2,000 L.

Editorial note

BIO CITY remains the key Northway expansion signal in Vilnius and strengthens the 2026 manufacturing footprint.

BIO CITY Vilnius cluster showcase
Watch note

BIO CITY is the scale thesis around Northway's verified Vilnius operating base. The live 2026 record remains the existing Northway manufacturing footprint; later campus phases stay segmented as expansion logic until they are operationally commissioned.

Note source
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026Last reviewed: 14 March 2026
Capabilities

Core capabilities

Primary declared technical activities and areas of operating focus.

Mammalian Cell Culture
Microbial Fermentation
Aseptic Filling
Process Development
Verification source dossier

Verification source dossier

Official source set used to support leadership, physical-site, certification, and watch-note evidence.

Leadership evidenceNorthway Biotech leadership team page.Source origin: northwaybiotech.comOpen source
Supporting evidenceNorthway Biotech BIO CITY expansion announcement.Source origin: northwaybiotech.comOpen source
Physical-site evidenceOfficial Northway Biotech Europe facilities page listing Mokslininku str. 4, Vilnius.Source origin: northwaybiotech.comOpen source
Strategic evidencebiocity.ltSource origin: biocity.ltOpen source
Infrastructure

Declared infrastructure

Bioreactors (up to 2000L)
HPLC/FPLC Systems
Regulatory posture

Quality system coverage

GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.

GMP
VERIFIED ACTIVE 2026
GLP
REVIEW IN PROGRESS 2026
ISO-13485
VERIFIED ACTIVE 2026
FDA-Inspected
REVIEW IN PROGRESS 2026
Verification history

Verification history

14 Mar 2026: Executive identity confirmed via official management disclosure.
14 Mar 2026: Full trust review completed.
FAQ

Frequently asked questions

Where is Northway Biotech located?
Northway Biotech operates from Mokslininku str. 4, LT-08412 Vilnius, Lithuania, Vilnius, Lithuania.
Who runs Northway Biotech?
Northway Biotech is led by Vladas Algirdas Bumelis, CEO and Chairman of the Board. Verified 14 Mar 2026.
What certifications does Northway Biotech hold?
Northway Biotech is documented under cGMP Manufacturing, GMP Certified, ISO 13485.
What does Northway Biotech do?
BIO CITY anchor with Grade A-D cleanrooms, biologics development-to-manufacturing transfer capability, and bioreactor infrastructure extending to 2,000 L. Core capabilities: Mammalian Cell Culture, Microbial Fermentation, Aseptic Filling, Process Development.
Editorial context

Related technical briefs

Briefs that name Vilnius as a covered market or city.